**Advanced Prostate**

**Castrate Resistant**

- Non-Metastatic
  - Hormone Naive
    - Non-Metastatic
      - IRB # 11268
        - Salvage radiation + enzalutamide/placebo for recurrent prostate cancer
      - IRB # 17717
        - Degarelix, apalutamide, abiraterone acetate in biochemically relapsed prostate cancer
    - Non-Metastatic
      - IRB # 19633
        - SWOG 1802: S ST +/-: definitive tx for metastatic disease
      - New Trial Coming Soon
  - Metastatic
    - IRB # 19558
      - Phase 3 Study of pembrolizumab/placebo plus enzalutamide (KN-641)
    - IRB # 18231
      - Phase 1/2a Study of CORT125281 and enzalutamide
    - IRB # 17864
      - Phase III Study of Rucaparib versus physician’s choice for patients with mCRPC associated with Homologous Recombination Deficiency
    - IRB # 18231
      - Phase 1/2a Study of CORT125281 and enzalutamide
    - IRB # 19782
      - PORTER: Multicenter, Open-Label Study to evaluate biomarkers and immunotherapy combinations
    - IRB # 18878
      - Phase 1 Study of FOR46 in mCRPC (FOR46-001)
    - IRB # 18878
      - Phase 1 Study of FOR46 in mCRPC (FOR46-001)
    - IRB # 20325
      - Phase 1 of HPN424 in Patients with mCRPC (HPN424-1001)

**Metastatic**

- No Trials Currently Available
- No Trials Currently Available
- IRB # 15921
  - INTERVAL: Intense exercise for survival among men with mCRPC
- IRB # 15944
  - Falls in Elderly Men Taking Enzalutamide
- IRB # 16837
  - International Registry for Men with Advanced Prostate Cancer
- IRB # 18084
  - S1609 DART – Rare Tumors
- IRB # 19633
  - SWOG 1802: S ST – Rare Tumors
- IRB # 19782
  - PORTER: Multicenter, Open-Label Study to evaluate biomarkers and immunotherapy combinations
- IRB # 18878
  - Phase 1 Study of FOR46 in mCRPC (FOR46-001)
- IRB # 20325
  - Phase 1 of HPN424 in Patients with mCRPC (HPN424-1001)
- IRB # 18878
  - Phase 1 Study of FOR46 in mCRPC (FOR46-001)
- IRB # 18878
  - Phase 1 Study of FOR46 in mCRPC (FOR46-001)
- IRB # 20325
  - Phase 1 of HPN424 in Patients with mCRPC (HPN424-1001)

**Supportive Care/Biomarker**

- IRB # 19558
  - S1609 DART – Rare Tumors
- IRB # 19782
  - PORTER: Multicenter, Open-Label Study to evaluate biomarkers and immunotherapy combinations
- IRB # 18878
  - Phase 1 Study of FOR46 in mCRPC (FOR46-001)
- IRB # 20325
  - Phase 1 of HPN424 in Patients with mCRPC (HPN424-1001)

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

12/5/2019